3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Editas Medicine's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -86.39%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Editas Medicine's 3-Year ROIIC % or its related term are showing as below:
EDIT's 3-Year ROIIC % is ranked worse than 71.21% of 1320
companies
in the Biotechnology industry
Industry Median: -4.42
vs EDIT: -86.39
Editas Medicine (NAS:EDIT) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Editas Medicine 3-Year ROIIC % Related Terms
Editas Medicine 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Editas Medicine's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EDIT vs SGMT, AUTL, FBRX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Editas Medicine's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Editas Medicine's 3-Year ROIIC % falls into.
Editas Medicine's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -99.336 (Dec. 2025) - -225.95 (Dec. 2022) )
/
( 40.445 (Dec. 2025) - 187.01 (Dec. 2022) )
=
126.614
/
-146.565
=
-86.39%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Editas Medicine (EDIT) has a 3-Year ROIIC % of -86.39 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Editas Medicine and its competitors. According to the industry distribution chart, Editas Medicine ranks #940 out of 1320 companies in the Biotechnology industry, placing it in the top 71.2%.
Is Editas Medicine's 3-Year ROIIC % too high?
Editas Medicine's current 3-Year ROIIC % is -86.39. Based on the distribution chart, Editas Medicine ranks #940 out of 1320 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Editas Medicine has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Editas Medicine's 3-Year ROIIC % compare to SGMT and AUTL?
According to the Biotechnology industry distribution chart, Editas Medicine ranks #940 out of 1320 companies for 3-Year ROIIC %. This places Editas Medicine in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Editas Medicine and its competitors. Editas Medicine's current 3-Year ROIIC % is -86.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Editas Medicine stock overvalued right now?
Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.86, compared to a current price of $3.64 — trading 95.7% above its estimated fair value. The current 3-Year ROIIC % is -86.39. Editas Medicine's overall GF Score™ is 45/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Editas Medicine (EDIT), the current 3-Year ROIIC % is -86.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Editas Medicine (EDIT) Overvalued in 2026?
Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued.
The current stock price of $3.64 is trading 95.7% above its estimated GF Value™ of $1.86.
GuruFocus considers Editas Medicine to be Significantly Overvalued.
Key valuation signals for EDIT:
3-Year ROIIC %: -86.39
GF Value™: $1.86 vs. price of $3.64 (95.7% above fair value)
No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
45GF Score
Get the complete analysis for EDIT
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EDIT has been successfully added to your 
